U.S. MDMA/PTSD Paper Revised and Resubmitted

U.S. MDMA/PTSD Paper Revised and Resubmitted; Long-Term Follow-Up Study Continues On Sunday May 9, a manuscript about our flagship U.S. MDMA/PTSD pilot study was resubmitted to a peer-reviewed journal …

MAPS Continues Protocol Development and Plann

In Spain, MAPS is in the protocol development stage for a study being conducted by Jose Carlos Bouso, Ph.D., Jordo Riba, Ph.D., and Manel Barbanoj M.D. Weve agreed upon the protocol design with this team …

MAPS Clinical Plan for End-of-Phase 2 Meeting

On Monday, March 22, MAPS received final approval from our Institutional Review Board (IRB) to move forward with our new MDMA/PTSD study. Michael Mithoefer, M.D. and Annie Mithoefer, BSN will conduct this …

MAPS MDMA Supply Analyzed for Quality

MAPS MDMA Supply Analyzed for Quality MAPS currently owns approximately 17 grams of MDMA. We are having the supply of MDMA reexamined for quality assurance. The analysis is intended to make sure that the …

Several MDMA/PTSD Protocol Documents Revised

Several MDMA/PTSD Protocol Documents Revised In light of the results from our US MDMA/PTSD pilot study and preliminary results from our Swiss and Israeli pilot studies, we have completed an overall review …

PDF File

Clinical Psychology Review. “Emerging treatments for PTSD.” By Judith Cukor, Josh Spitalnick, JoAnn Difede, Albert Rizzo, and Barbara O. Rothbaum This scientific, peer-reviewed paper has a …